NHS fast tracks access to Amgen’s just-approved KRAS cancer drugAmgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement Share XNHS fast tracks access to Amgen’s just-approved KRAS cancer drughttps://pharmaphorum.com/news/nhs-fast-tracks-access-to-amgens-just-approved-kras-cancer-drug/
Amgen offers hope in KRAS-mutated cancer with sotorasib read-outLast year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug Share XAmgen offers hope in KRAS-mutated cancer with sotorasib read-outhttps://pharmaphorum.com/news/amgen-offers-hope-in-kras/
